Targeting BCR-ABL with selective ABL tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML and has resulted in an excellent prognosis in patients with chronic phase CML [6]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.